Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
3
7
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Evidence suggests that neurotrophic tyrosine receptor kinase ( A systematic literature review was conducted in Medline, Embase, Cochrane, and PubMed to identify studies comparing the overall survival (OS) of patients with In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors In patients not treated with TRK inhibitor therapies, those with
Identifiants
pubmed: 37384865
doi: 10.1200/PO.22.00651
pmc: PMC10581655
doi:
Substances chimiques
tyrosine receptor
0
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200651Commentaires et corrections
Type : ErratumIn
Références
J Clin Epidemiol. 2013 Apr;66(4):408-14
pubmed: 23337781
PLoS One. 2022 Aug 8;17(8):e0270571
pubmed: 35939431
BMC Med Res Methodol. 2012 Feb 01;12:9
pubmed: 22297116
J Oncol Pharm Pract. 2020 Dec;26(8):2015-2019
pubmed: 32957860
Target Oncol. 2021 May;16(3):389-399
pubmed: 33893941
Invest New Drugs. 2022 Feb;40(1):157-162
pubmed: 34341905
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Ther Adv Med Oncol. 2020 Dec 21;12:1758835920975613
pubmed: 33425024
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Stat Med. 2015 Mar 15;34(6):984-98
pubmed: 25475839
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Clin Cancer Res. 2022 Apr 1;28(7):1302-1312
pubmed: 35144967
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Gastroenterology. 2011 May;140(5):1410-26
pubmed: 21406195
Cancer Treat Res Commun. 2022;33:100623
pubmed: 36041373
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622